Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Capricor Therapeutics (CAPR) over the last 13 years, with Q3 2025 value amounting to $59167.0.

  • Capricor Therapeutics' Receivables - Other fell 8555.78% to $59167.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $59167.0, marking a year-over-year decrease of 8555.78%. This contributed to the annual value of $10.4 million for FY2024, which is 3.38% down from last year.
  • Per Capricor Therapeutics' latest filing, its Receivables - Other stood at $59167.0 for Q3 2025, which was down 8555.78% from $59509.0 recorded in Q2 2025.
  • In the past 5 years, Capricor Therapeutics' Receivables - Other ranged from a high of $10.4 million in Q4 2023 and a low of $59167.0 during Q3 2025
  • Moreover, its 5-year median value for Receivables - Other was $409682.0 (2024), whereas its average is $1.4 million.
  • In the last 5 years, Capricor Therapeutics' Receivables - Other surged by 179415.12% in 2023 and then tumbled by 8555.78% in 2025.
  • Over the past 5 years, Capricor Therapeutics' Receivables - Other (Quarter) stood at $391750.0 in 2021, then surged by 39.78% to $547580.0 in 2022, then soared by 1794.15% to $10.4 million in 2023, then dropped by 0.03% to $10.4 million in 2024, then tumbled by 99.43% to $59167.0 in 2025.
  • Its last three reported values are $59167.0 in Q3 2025, $59509.0 for Q2 2025, and $59834.0 during Q1 2025.